Recombinant LCAT ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 259 | Lecithin-cholesterol acyltransferase deficiency | 1 |
259. Lecithin-cholesterol acyltransferase deficiency
Clinical trial : 1 / Drug : 1 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04737720 (ClinicalTrials.gov) | January 24, 2013 | 3/2/2021 | Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT) | Analysis of Samples Collected From a Subject Who Received ACP- 501 (Human Recombinant Lecithin:Cholesterol Acyltransferase [rhLCAT]) | Familial LCAT Deficiency | Drug: Recombinant LCAT | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 18 Years | 100 Years | All | 1 | United States |